Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

BackgroundTolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment.MethodsA prospective study of an initial cohort...

Full description

Bibliographic Details
Main Authors: Javier Naranjo, Francisco Borrego, José Luis Rocha, Mercedes Salgueira, Maria Adoración Martín-Gomez, Cristhian Orellana, Ana Morales, Fernando Vallejo, Pilar Hidalgo, Francisca Rodríguez, Remedios Garófano, Isabel González, Rafael Esteban, Mario Espinosa
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
glomerular filtration rate (eGFR)
hepatic toxicity
polycystic kidney disease (PKD)
tolvaptan
urinary osmolality
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.987092/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.987092/full

Similar Items